Literature DB >> 2975670

Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells.

J D Katz1, P Nishanian, R Mitsuyasu, B Bonavida.   

Abstract

The acquired immunodeficiency syndrome (AIDS) is defined in clinical terms by the development of Kaposi's sarcoma and/or severe opportunistic infections in persons without predisposing conditions. A hallmark of the syndrome has been a decrease in the number of CD4+ T helper cells. The reduction in the frequency of the CD4+ lymphocytes has been postulated to be primarily the result of human immunodeficiency virus (HIV) tropism and cytophathogenicity for the T-cell subset. Yet only a small percentage of cells in actually infected with HIV. Recently, we provided evidence indicating that AIDS patients' natural killer cells can mediate normal levels of antibody-dependent cellular cytotoxicity (ADCC) despite exhibiting a defect in natural killer (NK) effector function (J Immunol 139:55, 1987). This finding prompted us to investigate whether AIDS patients' effector cells could mediate ADCC against circulating CD4+ T cells infected with or expressing HIV antigen. The findings reported herein demonstrate that AIDS effector cells can mediate lysis of CEM (CD4+ T-cell line) coated with HIV protein in the presence of HIV-specific antibody. Lysis was specific, as non-HIV-coated CEM or the addition of HIV-negative serum resulted in no lysis. We then examined HIV-coated peripheral blood-derived CD4+ T lymphocytes as targets in ADCC. We demonstrate that in the presence of HIV-specific antibody, HIV-coated CD4+ T lymphocytes serve as targets for ADCC by AIDS effector cells. The lytic activity obtained with AIDS effector cells was comparable to that obtained with normal effector cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2975670     DOI: 10.1007/bf00916950

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  12 in total

1.  Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1986-05-23       Impact factor: 17.586

2.  Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

Authors:  H K Lyerly; T J Matthews; A J Langlois; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

3.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

Review 4.  Immunologic abnormalities in the acquired immunodeficiency syndrome.

Authors:  H C Lane; A S Fauci
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

5.  A simple and rapid method for preparation of HIV-expressing targets for functional assays.

Authors:  P G Nishanian; E Ojo-Amaize; C H Uittenbogaart; J V Giorgi
Journal:  J Immunol Methods       Date:  1988-03-16       Impact factor: 2.303

6.  Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.

Authors:  J D Katz; R Mitsuyasu; M S Gottlieb; L T Lebow; B Bonavida
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

7.  Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages.

Authors:  K Ljunggren; B Böttiger; G Biberfeld; A Karlson; E M Fenyö; M Jondal
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

8.  Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2.

Authors:  B Bonavida; J Katz; M Gottlieb
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

9.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

View more
  6 in total

1.  Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression.

Authors:  E Ojo-Amaize; P G Nishanian; D F Heitjan; A Rezai; I Esmail; E Korns; R Detels; J Fahey; J V Giorgi
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

2.  Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection.

Authors:  U Ziegner; D Campbell; K Weinhold; I Frank; R Rutstein; S E Starr
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

3.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

4.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

Review 5.  Plasma Membrane-Associated Restriction Factors and Their Counteraction by HIV-1 Accessory Proteins.

Authors:  Peter W Ramirez; Shilpi Sharma; Rajendra Singh; Charlotte A Stoneham; Thomas Vollbrecht; John Guatelli
Journal:  Cells       Date:  2019-09-02       Impact factor: 6.600

6.  Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse.

Authors:  S K Stanley; J M McCune; H Kaneshima; J S Justement; M Sullivan; E Boone; M Baseler; J Adelsberger; M Bonyhadi; J Orenstein
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.